Welcome to our dedicated page for Bicara Therapeutics SEC filings (Ticker: BCAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles U.S. Securities and Exchange Commission (SEC) filings for Bicara Therapeutics Inc. (NASDAQ: BCAX), a clinical-stage biopharmaceutical company developing the bifunctional antibody ficerafusp alfa for solid tumors. As a public issuer, Bicara submits periodic and current reports that provide detail on its financial position, research and development spending, and key clinical and corporate events.
Among the filings available for review are Form 10-K annual reports and Form 10-Q quarterly reports, which describe operating expenses, including research and development and general and administrative costs, as well as cash, cash equivalents, and investments. These documents give insight into how Bicara funds the pivotal FORTIFI-HN01 trial in recurrent/metastatic head and neck squamous cell carcinoma and its Phase 1/1b expansion cohorts in head and neck cancer and metastatic colorectal cancer.
Form 8-K current reports, such as those referenced in the provided data, furnish press releases on quarterly financial results and business updates. These filings often summarize recent clinical milestones for ficerafusp alfa, including dose-optimization progress, expansion cohort data, and regulatory developments like Breakthrough Therapy Designation from the U.S. Food and Drug Administration.
Investors can also use this page to access exhibits attached to Bicara’s SEC filings, which may include detailed financial statements, risk factor discussions, and other disclosures relevant to evaluating a clinical-stage biotechnology company. Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy reports, helping readers quickly identify information on operating expenses, cash runway, clinical trial status, and other factors that influence the outlook for BCAX.
Schedule 13G/A (Am. No. 1) filed for Bicara Therapeutics Inc. (BCAX) shows that investment entities affiliated with Invus have built a passive 9.6 % stake in the company’s common stock as of 30 Jun 2025.
- Invus Public Equities, L.P. directly owns 4,861,944 shares (8.9 %).
- Avicenna Life Sci Master Fund LP holds 355,025 shares (0.7 %).
- Through control of multiple GP/LLC vehicles, Raymond Debbane is deemed to beneficially own a combined 5,216,969 shares, representing the full 9.6 %.
Percentages are based on 54,536,218 shares outstanding reported in the issuer’s 13 May 2025 10-Q. The filing is made under Rule 13d-1(c) and includes the standard certification that the securities were not acquired to change or influence control, indicating a passive investment approach.
The appearance of a sophisticated life-sciences investor just below the 10 % threshold may improve market confidence and liquidity but does not signal activist intent at this stage.
Bicara Therapeutics Inc. (BCAX) – Form 4 insider filing dated 18 Jun 2025 reports transactions by Chief Legal Officer Lara Meisner.
Non-derivative activity: On 16 Jun 2025 Meisner exercised 15,829 options for common stock at an exercise price of $5.45 per share and immediately sold the same 15,829 shares at a weighted-average price of $10.43 (individual sales executed between $10.03-$10.84). As a result, her direct common-stock ownership fell to 0 shares.
Derivative holdings: Two option grants were partially exercised. After the transactions Meisner still directly holds 60,854 options with a $5.45 strike expiring 10 Dec 2033 and 97,443 options with the same strike and expiry, for a total of 158,297 remaining options.
- Grant #1 vests in 16 equal quarterly installments from 14 Dec 2023.
- Grant #2 vested 25 % on 27 Nov 2024; the balance vests in 12 equal quarterly installments thereafter.
Rule 10b5-1 plan: All trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on 13 Nov 2024, as disclosed in the Explanation of Responses.
The filing reflects routine option exercise and monetisation by an executive officer, with no change to derivative exposure but the elimination of directly held common shares.